Ann: 2011 Annual Report , page-3

This is very informative for all those who felt that the announcement of an own pain patch development would be a step back:

Homecare and Hygiene applications were new areas of consideration last year, but along with personal care these
areas offer opportunities for a shorter time to market. Partnering activities remain a critical focus for OBJ, but as
made apparent by our recent announcement, when clear business opportunities are identified OBJ is prepared to
adopt a first-mover approach. Musculoskeletal pain treatment and prevention is an area where OBJ technology
offers potential unique benefits, something the Company will be pro-actively exploring with a view to a future
partnership or possible direct launch into the market place.

Clear business opportunities are identified on the back of progressing partnering activities.
It is as we speculated, the own pain patch is indeed a program envisaged through already existing research of partner programs and identified as an area where OBJ can make the largest financial impact by being there first.

No doubt that the fact Edwards co-owns the patent for Tripeptofen plays into this.
Our own labatories which are now fully equipped, in addition to the UK presence, allows such approach.